Inflammation is known to play a significant role in the process of atherogenesis and cardiovascular disease (CVD). Indeed, patients with chronic inflammatory diseases are at increased risk for cardiovascular events. The mechanisms linking chronic inflammation and CVD however remain poorly understood. Psoriasis, a chronic inflammatory skin disease associated with a greater risk of early cardiovascular events, provides a suitable human model to study the pathophysiology of inflammatory atherogenesis in humans. Additionally, cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)17A and other immune pathways are the common links between the pathogenesis of psoriasis and atherosclerosis, and hence the approved treatments for psoriasis, which include selective cytokine inhibition (e.g. anti-TNF, anti-IL17A, anti-IL12/23) and immune modulation (e.g. methotrexate, cyclosporine), provide an opportunity to examine the effect of modulating these pathways on atherogenesis. We have been utilizing this human model in a large, prospective cohort study, and this review will summarize our approach and results of utilizing this human model to study inflammatory atherogenesis. Specifically, we will review simultaneous multi-modal imaging of several vascular beds using FDG-PET/CT, FDG-PET/MRI and coronary CT angiography, as well as cardiovascular biomarkers, to better understand how modulation of inflammation may impact vascular diseases.
- Cardiovascular Imaging
- 18-FDG PET/CT
- Copyright © 2016, American Journal of Physiology-Heart and Circulatory Physiology